Hello,

We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

  • NIAID
  • Rewriting Life

    Gulp. These Volunteers Are Swallowing E. Coli Pills to Help Medicine

    Biologists are genetically modifying the DNA of stomach bacteria so they act like living drugs.

    • by Antonio Regalado
    • September 26, 2017
    • E. coli bacteria as seen through a microscope.

    Somewhere in Baltimore, volunteers are gulping capsules filled with GMOs—gene-modified E. coli bacteria, to be precise.

    Synlogic of Cambridge, Massachusetts, the company behind the unusual study, is testing what it calls “synthetic biotics,” or bacteria engineered to carry out specialized jobs in a person’s stomach.

    Inside the pills are E. coli engineered to sop up ammonia inside the gut of people who can’t get rid of it fast enough. The study signals how genetic engineers are hoping to harness the microbiome, as the trillions of microscopic organisms that dwell within you are known.

    The drug is designed to help people suffering from disorders of the “urea cycle.” That’s the metabolic flywheel inside your liver that gets rid of excess nitrogen. For people whose urea cycles are faulty, excess nitrogen turns into ammonia, just like what’s under your kitchen sink, and just as hazardous.

    Though the condition is rare, for some people it’s serious enough to require a liver transplant.

    This study, which began in June, doesn’t yet involve any sick patients. Instead, it’s a safety trial. The volunteers taking the drug collect a fee for swallowing GM germs to advance knowledge. They have to live in a testing facility for as long as three weeks so technicians can monitor them and collect their poop for DNA analysis.

    Of the 50 people the trial is meant to study, Synlogic CEO J.C. Gutierrez-Ramos says “many” have already taken the new GMO pill. Others, picked at random, have gotten a placebo. The trial is being carried out at one hospital in Maryland.

    The drug represents a concrete application of synthetic biology, which is the idea of engineering an organism’s metabolism to produce fuel, drugs, perfumes, or other chemicals. Previously, a company called ActoGenix undertook studies in Europe of a GM version of the bacterium Lactococcus lactis that it had altered so it released a protein drug. In the U.S., Marina Biotech also carried out a small safety test of anti-cancer bacteria, also genetically modified.

    The U.S. Food and Drug Administration, which considers such drugs to be “live biological products,” this summer fast-tracked Synlogic’s application to try it on people. Gutierrez-Ramos says Synlogic will know if it’s safe by December and hopes to start up studies in actual patients next year.

    Tech Obsessive?
    Become an Insider to get the story behind the story — and before anyone else.

    Subscribe today

    Uh oh–you've read all of your free articles for this month.

    Insider Premium
    $179.95/yr US PRICE

    More from Rewriting Life

    Reprogramming our bodies to make us healthier.

    Want more award-winning journalism? Subscribe to Insider Plus.
    • Insider Plus {! insider.prices.plus !}*

      {! insider.display.menuOptionsLabel !}

      Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

      See details+

      What's Included

      Unlimited 24/7 access to MIT Technology Review’s website

      The Download: our daily newsletter of what's important in technology and innovation

      Bimonthly print magazine (6 issues per year)

      Bimonthly digital/PDF edition

      Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

      Special interest publications

      Discount to MIT Technology Review events

      Special discounts to select partner offerings

      Ad-free web experience

    /
    You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.